Recent Updates — SILO
On October 13, 2026, Silo Pharma entered into an asset purchase agreement to acquire certain software and related intellectual property from Larry King. In consideration, the company issued 150,000 shares of common stock subject to a twelve-month lock-up period. The transaction was conducted under Section 4(a)(2) of the Securities Act. Silo Pharma operates in the pharmaceutical industry.
On October 1, 2026, Silo Pharma, Inc. entered into an asset purchase agreement with Norsight Consulting Inc. to acquire certain software, technology, and related intellectual property. In consideration for these assets, the Company issued a warrant to purchase up to 300,000 shares of its common stock at an exercise price of $1.51 per share. The warrant includes a cashless exercise feature, is exercisable beginning April 1, 2027, and expires on September 30, 2031. The transaction involved unregistered sales of equity securities relied upon under Section 4(a)(2) of the Securities Act. Silo Pharma, Inc. operates in the pharmaceutical industry.
On August 18, 2026, Silo Pharma, Inc. entered into an asset purchase agreement with Parkview Consulting LLC to acquire certain software, technology, domain names, and related intellectual property. In consideration for these assets, the Company issued 165,000 shares of its common stock to Corwin Yu, the sole member of the Seller and a lead strategic advisor on the Company’s Cryptocurrency Advisory Board. The issued shares are subject to a lock-up period lasting twelve months or until a Change in Control. Silo Pharma, Inc. operates in the pharmaceutical industry.
Silo Pharma, Inc. announced that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement of $1.00 per share. The company's closing bid price was at or above $1.00 from June 3, 2026, through June 16, 2026, resolving the compliance issue. Silo Pharma, Inc. is a pharmaceutical company focused on developing and commercializing specialized drug delivery technologies and specialized drug products.